Article

Correcting The Blind Spot In Accountability: The Role Of Pharmacy Care

CMS stated that they seek recommendations about how the ACO program might evolve to "encourage greater care integration and financial accountability."

The Centers for Medicare and Medicaid Services (CMS) recently issued a Request for Information (RFI) to solicit suggestions about how to improve the Accountable Care Organization (ACO) programs. CMS stated that they seek recommendations about how the ACO program might evolve to “encourage greater care integration and financial accountability.”

The RFI explicitly stated that they seek information about how to better integrate Part D expenditures into ACO cost calculations to make pharmaceuticals part of the approach to care delivery and health care transformation.

The deadline for comments about encouraging Part D integration in ACOs has now passed. But the issue extends beyond ACOs. In addition, bundled payments and patient-centered medical home programs target hospitals and primary care providers to promote higher quality and lower cost care. All these programs have largely excluded prescription drug costs in their calculus, and offer no direct incentives for Part D plans to participate in and improve care.

Read the full story here: http://bit.ly/1jirpoa

Source: Health Affairs

Related Videos
Sam Peasah, PhD, MBA, RPh, director for the Center of High-Value Health Care at the University of Pittsburgh Medical Center (UPMC)
JC Scott, CEO and president of The Pharmaceutical Care Management Association (PCMA)
Galen Shearn-Nance, BS, and Johnie Rose, MD, PhD
Galen Shearn-Nance, BS
Dr Johnie Rose
Adam Colburn, JD, associate vice president for congressional affairs, AMCP
Neha Kashalikar, PharmD, director of strategic pharmacy consulting, MassHealth
Jorge García, PharmD, MS, MBA, MHA, FACHE, FACCC
Tiffany Meng, PharmD, oncology pharmacist, UCSF Health
Dr Andrew S. Oseran
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo